Duo to equally share development costs and profits from any candidates emerging from their RNAi discovery pact.
Regeneron Pharmaceuticals Inc. and Alnylam Pharmaceuticals Inc. are joining forces to investigate genetic factors underlying chronic liver disease, identify new therapeutic targets and then progressing likely RNAi candidates, sharing the costs and potential profits equally from any resulting products.
The move reflects the promise that RNA interference (RNAi) therapeutics offer in specifically targeting and silencing genes
The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.
The sector is continuing to show resilience despite financial and market challenges.
Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.
The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.
Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.
The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.
PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.
